CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today detailed its accelerating financial recovery and other factors underpinning its value, at a meeting with investors and securities analysts in New York. Genzyme convened the meeting to present its near-term financial outlook, report progress on its actions to enhance shareholder value, communicate expectations for its late-stage pipeline, and outline why the Sanofi-Aventis’ tender offer of $69-per-share dramatically undervalues the company.
